Microphysiological Systems Organ On A Chip Market
Microphysiological Systems (Organ-on-a-Chip) Market Forecasts to 2034 - Global Analysis By Product (Single-Organ-on-a-Chip Systems, Multi-Organ (Body-on-a-Chip) Systems, Disease-Specific Chip Models, High-Throughput Screening Platforms, Integrated Organ-on-Chip Workstations, Modular & Customizable Chip Platforms, Other Products), By Organ Type, By Component, By Material, By Application and By Geography
According to Stratistics MRC, the Global Microphysiological Systems (Organ-on-a-Chip) Market is accounted for $307.61 million in 2026 and is expected to reach $448.33 million by 2034 growing at a CAGR of 35.2% during the forecast period. Microphysiological Systems (Organ-on-a-Chip) are advanced microfluidic devices that replicate the structure and function of human organs using living cells arranged in engineered environments. These systems simulate physiological conditions such as blood flow, mechanical forces, and cellular interactions, enabling realistic models of organs like the lung, liver, heart, or brain. They are widely used in drug discovery, toxicity testing, and disease modeling. By providing human-relevant biological insights, organ-on-a-chip platforms reduce reliance on animal testing, improve predictive accuracy in preclinical studies, and accelerate pharmaceutical research and personalized medicine development.
Market Dynamics:
Driver:
Rising demand for advanced drug testing
Traditional animal models and 2D cell cultures often fail to replicate human physiological responses, leading to high drug failure rates during clinical trials. Organ-on-a-chip technologies provide microengineered environments that mimic the structure and function of human organs. This enables researchers to better evaluate drug toxicity, efficacy, and pharmacokinetics before clinical testing. Pharmaceutical companies are increasingly adopting these systems to reduce development costs and improve success rates. As the pharmaceutical industry focuses on safer and faster drug development, demand for advanced testing platforms continues to grow.
Restraint:
Lack of standardized validation protocols
Different research institutions and companies often use varied chip designs, cell sources, and testing methodologies. This lack of uniform standards makes it difficult to compare results across laboratories. Regulatory agencies also require consistent validation data before accepting organ-on-chip systems for drug approval processes. Without globally accepted testing frameworks, pharmaceutical companies may hesitate to fully integrate these systems into their pipelines. The need for regulatory clarity and standardized guidelines is therefore critical for widespread market adoption.
Opportunity:
Integration with AI-driven drug discovery
AI technologies can analyze complex biological data generated from microphysiological systems to predict drug responses more accurately. Combining AI with organ-on-chip platforms enables high-throughput screening and improved modeling of disease mechanisms. This approach helps researchers identify promising drug candidates faster while reducing experimental errors. AI-powered analytics can also optimize chip design and experimental parameters. As pharmaceutical companies increasingly adopt digital and data-driven research methods, the synergy between AI and organ-on-chip technology is expected to accelerate innovation.
Threat:
Competition from traditional cell culture models
Conventional methods are widely established, inexpensive, and familiar to researchers across laboratories. Many pharmaceutical companies already have infrastructure and expertise built around 2D and 3D cell culture systems. Transitioning to organ-on-chip platforms may require additional investment in equipment and training. Furthermore, some early-stage research applications may still rely on simpler models that are easier to implement. This ongoing reliance on conventional models may slow the widespread adoption of microphysiological systems.
Covid-19 Impact:
The COVID-19 pandemic had a mixed but overall positive impact on the Microphysiological Systems market. During the pandemic, researchers sought advanced models to study viral infections and evaluate potential therapeutics. Organ-on-chip platforms were used to replicate human lung and immune responses to SARS-CoV-2. This accelerated research interest and investment in microphysiological technologies. However, supply chain disruptions and temporary laboratory shutdowns initially slowed research activities. Funding priorities also shifted toward pandemic-related projects.
The liver-on-a-chip segment is expected to be the largest during the forecast period
The liver-on-a-chip segment is expected to account for the largest market share during the forecast period as the liver plays a crucial role in drug metabolism and toxicity assessment. Pharmaceutical companies prioritize evaluating hepatotoxicity early in the drug development process. Liver-on-chip models closely mimic human liver microarchitecture and biochemical responses. These systems allow researchers to study metabolic interactions and long-term drug effects more accurately than traditional cell cultures. The high incidence of drug-induced liver injury in clinical trials further drives demand for reliable liver models.
The personalized medicine segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the personalized medicine segment is predicted to witness the highest growth rate due to increasing interest in patient-specific treatment approaches. Organ-on-chip platforms can incorporate cells derived from individual patients to model disease conditions more precisely. This enables researchers to evaluate how different patients respond to specific drugs or therapies. Such capabilities are particularly valuable in complex diseases like cancer and neurological disorders. Pharmaceutical companies and research institutions are increasingly investing in personalized treatment development.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and high investment in biomedical innovation. The region hosts many leading biotechnology firms, pharmaceutical companies, and academic research institutions. Government agencies and private investors actively fund research related to advanced drug testing technologies. Additionally, collaborations between universities and industry players accelerate technological advancements in organ-on-chip platforms. The presence of major market participants further strengthens regional growth.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by increasing pharmaceutical research activities and expanding biotechnology sectors. Countries such as China, Japan, South Korea, and India are investing heavily in life science research infrastructure. Growing collaborations between global pharmaceutical companies and regional research institutions also contribute to market expansion. Governments in the region are supporting innovation through funding programs and biotechnology initiatives. Additionally, the rising demand for advanced drug testing technologies is boosting adoption of organ-on-chip systems.
Key players in the market
Some of the key players in Microphysiological Systems (Organ-on-a-Chip) Market include Emulate, Inc., CN Bio Innovations Ltd., MIMETAS BV, TissUse GmbH, InSphero AG, AxoSim, Inc., Kirkstall Ltd., Nortis Inc., AlveoliX AG, Hesperos, Inc., Cherry Biotech, Altis Biosystems, NETRI, Draper Laboratory and Organovo Holdings, Inc.
Key Developments:
In June 2025, Emulate launched the AVA Emulation System, a high-throughput benchtop instrument that automates the culture, incubation, and real-time imaging of up to 96 independent Organ-Chip samples simultaneously. The system utilizes the new Chip-Array consumable and is designed to integrate with standard laboratory workflows, reducing consumable costs by four-fold and hands-on time by more than half compared to previous technologies.
In April 2025, CN Bio entered a long-term strategic partnership with Pharmaron to validate and integrate its PhysioMimix® OOC technology into Pharmaron's global R&D platform, focusing on disease modelling, toxicity testing, and ADME studies . The agreement includes the installation of PhysioMimix instruments at Pharmaron's global facilities to co-develop new applications addressing unmet needs in drug discovery.
Products Covered:
• Single-Organ-on-a-Chip Systems
• Multi-Organ (Body-on-a-Chip) Systems
• Disease-Specific Chip Models
• High-Throughput Screening Platforms
• Integrated Organ-on-Chip Workstations
• Modular & Customizable Chip Platforms
• Other Products
Organ Types Covered:
• Liver-on-a-Chip
• Heart-on-a-Chip
• Lung-on-a-Chip
• Kidney-on-a-Chip
• Skin & Barrier Models
• Other Organ Types
Components Covered:
• Microfluidic Chips
• Cell Lines & Organoids
• Reagents & Media
• Pumps & Flow Controllers
• Other Components
Materials Covered:
• PDMS
• Thermoplastics
• Glass-Based Chips
• Silicon-Based Platforms
• Hydrogel Matrices
• Other Materials
Applications Covered:
• Drug Discovery & Screening
• Toxicology Testing
• Disease Modeling
• Personalized Medicine
• Other Applications
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product
5.1 Single-Organ-on-a-Chip Systems
5.2 Multi-Organ (Body-on-a-Chip) Systems
5.3 Disease-Specific Chip Models
5.4 High-Throughput Screening Platforms
5.5 Integrated Organ-on-Chip Workstations
5.6 Modular & Customizable Chip Platforms
5.7 Other Products
6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type
6.1 Liver-on-a-Chip
6.2 Heart-on-a-Chip
6.3 Lung-on-a-Chip
6.4 Kidney-on-a-Chip
6.5 Skin & Barrier Models
6.6 Other Organ Types
7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component
7.1 Microfluidic Chips
7.2 Cell Lines & Organoids
7.3 Reagents & Media
7.4 Pumps & Flow Controllers
7.5 Other Components
8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material
8.1 PDMS
8.2 Thermoplastics
8.3 Glass-Based Chips
8.4 Silicon-Based Platforms
8.5 Hydrogel Matrices
8.6 Other Materials
9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application
9.1 Drug Discovery & Screening
9.2 Toxicology Testing
9.3 Disease Modeling
9.4 Personalized Medicine
9.5 Other Applications
10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Geography
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 Strategic Market Intelligence
11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment
12 Industry Developments and Strategic Initiatives
12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives
13 Company Profiles
13.1 Emulate, Inc.
13.2 CN Bio Innovations Ltd.
13.3 MIMETAS BV
13.4 TissUse GmbH
13.5 InSphero AG
13.6 AxoSim, Inc.
13.7 Kirkstall Ltd.
13.8 Nortis Inc.
13.9 AlveoliX AG
13.10 Hesperos, Inc.
13.11 Cherry Biotech
13.12 Altis Biosystems
13.13 NETRI
13.14 Draper Laboratory
13.15 Organovo Holdings, Inc.
List of Tables
1 Global Microphysiological Systems (Organ-on-a-Chip) Market Outlook, By Region (2023-2034) ($MN)
2 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product (2023–2034) ($MN)
3 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Single-Organ-on-a-Chip Systems (2023–2034) ($MN)
4 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Multi-Organ (Body-on-a-Chip) Systems (2023–2034) ($MN)
5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease-Specific Chip Models (2023–2034) ($MN)
6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By High-Throughput Screening Platforms (2023–2034) ($MN)
7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Integrated Organ-on-Chip Workstations (2023–2034) ($MN)
8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Modular & Customizable Chip Platforms (2023–2034) ($MN)
9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Products (2023–2034) ($MN)
10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type (2023–2034) ($MN)
11 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Liver-on-a-Chip (2023–2034) ($MN)
12 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Heart-on-a-Chip (2023–2034) ($MN)
13 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Lung-on-a-Chip (2023–2034) ($MN)
14 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Kidney-on-a-Chip (2023–2034) ($MN)
15 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Skin & Barrier Models (2023–2034) ($MN)
16 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Organ Types (2023–2034) ($MN)
17 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component (2023–2034) ($MN)
18 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Microfluidic Chips (2023–2034) ($MN)
19 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Cell Lines & Organoids (2023–2034) ($MN)
20 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Reagents & Media (2023–2034) ($MN)
21 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Pumps & Flow Controllers (2023–2034) ($MN)
22 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Components (2023–2034) ($MN)
23 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material (2023–2034) ($MN)
24 Global Microphysiological Systems (Organ-on-a-Chip) Market, By PDMS (2023–2034) ($MN)
25 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Thermoplastics (2023–2034) ($MN)
26 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Glass-Based Chips (2023–2034) ($MN)
27 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Silicon-Based Platforms (2023–2034) ($MN)
28 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Hydrogel Matrices (2023–2034) ($MN)
29 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Materials (2023–2034) ($MN)
30 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application (2023–2034) ($MN)
31 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Drug Discovery & Screening (2023–2034) ($MN)
32 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Toxicology Testing (2023–2034) ($MN)
33 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease Modeling (2023–2034) ($MN)
34 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Personalized Medicine (2023–2034) ($MN)
35 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Applications (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
